ALDX - CIK 0001341235
The table below shows Aldeyra Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.04M | $54.53M | $144.42M | $144.42M | $229.79M | $77.86M |
| Short-term investments | $46.62M | $46.62M | $29.88M | $29.88M | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $71.78M |
| $104.07M |
| $147.81M |
| $181.02M |
| $232.75M |
| $83.06M |
| Property, plant & equipment | - | $0.00 | $5.76K | $19.28K | $32.49K | $59.92K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $72.06M | $104.61M | $148.33M | $181.29M | $233.14M | $83.35M |
| Accounts payable | $158.46K | $180.45K | $1.34M | $133.63K | $1.02M | $381.64K |
| Total current liabilities | $27.81M | $18.60M | $22.26M | $15.36M | $11.77M | $12.41M |
| Long-term debt | $0.00 | $15.00M | $0.00 | $14.92M | $15.50M | $11.43M |
| Total liabilities | $27.81M | $33.60M | $28.53M | $30.28M | $27.40M | $23.84M |
| Retained earnings | -$483.96M | -$450.11M | -$394.26M | -$356.72M | -$294.69M | -$236.92M |
| Total equity | $44.25M | $71.00M | $119.80M | $151.01M | $205.74M | $59.51M |